ClinicalTrials.gg
RecruitingNCT07208448Updated Jul 30, 2026

Voll Degradable Shoulder Spacer FIH Study

An interventional study of Voll Degradable Shoulder Spacer in Massive Rotator Cuff Tear, sponsored by Voll Medical Technologies Ltd.. Recruiting at 4 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Voll Medical Technologies Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

The Voll Degradable Shoulder Spacer First-in-Human study aims to evaluate the initial safety, effectiveness, and clinical outcomes of a degradable shoulder spacer in over 50 years old patients with symptomatic massive rotator cuff tears (MRCT).

02

Conditions studied

  • Massive Rotator Cuff Tear

Browse trials for

03

In context

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

This study's planned enrollment of 20 is below the median of 60 across 456 interventional studies indexed under Rotator Cuff Injuries.

Browse Rotator Cuff Injuries studies →

Lead sponsor

Voll Medical Technologies Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Full thickness MRCT.
  • Male or female patients ≥ fifty (50) years of age, in general good health, independent, and can comply with all post-operative evaluations and visits.

Main Exclusion Criteria:

  • Documented evidence of a history of drug/alcohol abuse within 1 year of enrollment.
  • Concurrent participation in any other clinical study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Voll Degradable Shoulder Spacer

    Device: Voll Degradable Shoulder Spacer

Interventions

  • DeviceVoll Degradable Shoulder Spacer

    Voll Degradable Shoulder Spacer

06

What researchers measure

Primary outcomes

  1. Device-related Serious Adverse Events

    Incidence of device-related serious adverse events (DRSAEs) related to the spacer.

    Time frame: Up to 12 months post-implantationץ

07

Study locations

3 of 4 sites recruiting
  • Assuta Ashdod Hospital
    Ashdod, Israel
    Recruiting
    • Sahar Boostenay · Contactsahar@vollmedical.com · +97254421243
    • Ran Atzmon, MD · Principal investigator
    • Yariv Goldstein, MD · Sub investigator
  • Ichilov (Sourasky Medical Center)
    Tel Aviv, Israel
    Not yet recruiting
    • Sahar Boostenay · Contactsahar@vollmedical.com · +972544621243
    • Efi Kazum, MD · Principal investigator
    • Eran Maman, MD · Sub investigator
  • Humanitas Gavazzeni Castelli
    Bergamo, Bergamo 24125, Italy
    Recruiting
    • Sahar Boostenay · Contactsaharb@vollmedical.com · +972544621243
    • Vincenzo Condello, MD · Principal investigator
    • Vincenzo Madonna, MD · Sub investigator
    • Marco Collarile, MD · Sub investigator
  • Istituto Ortopedico Rizzoli
    Bologna, Bologna 40136, Italy
    Recruiting
    • Sahar Boostenay · Contactsaharb@vollmedical.com · +972544621243
    • Stefano Zaffagnini, Prof. · Principal investigator
    • Federico Coliva, MD · Sub investigator
    • Vitogaetano Rinaldi, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 252 interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Oct 6, 2025
StartActual
Dec 9, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07208448
Lead sponsor
Voll Medical Technologies Ltd.
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Dec 9, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion